Physician profile
Anna Mousse
NPI 1073399085
$3,210.48
in general payments reported to CMS, 2019-2025
20 companies · $697 in 2025
The $697 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $652 · 2024: $1,861 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,210.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $394.08 | 2023-2025 | |
| Dermavant Sciences, INC. | $373.70 | 2024 | Vtama |
| Pfizer INC. | $355.59 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $251.46 | 2024-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $210.32 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $204.20 | 2023-2024 | Sotyktu |
| Galderma Laboratories, L.P. | $182.07 | 2024-2025 | Nemluvio |
| Revance Therapeutics, INC. | $163.08 | 2024 | Daxxify |
| Novartis Pharmaceuticals Corporation | $160.47 | 2023-2025 | |
| Incyte Corporation | $152.90 | 2023-2024 | Opzelura |
| Genzyme Corporation | $134.80 | 2023 | |
| Ucb, INC. | $125.36 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $118.33 | 2023-2025 | Dupixent, Libtayo |
| Merz North America, INC. | $104.62 | 2024 | |
| Lilly USA, LLC | $93.05 | 2025 | Taltz, Ebglyss |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $52.50 | 2024-2025 | Otezla, Otezla |
| Organon LLC | $51.07 | 2025 | Vtama |
| Leo Pharma INC. | $40.37 | 2023-2024 | Adbry |
| Biofrontera INC. | $25.37 | 2024 | Xepi, Bf-Rhodoled, Rhodoled Xl |
| Solta Medical, A Division of Bausch Health US, LLC | $17.14 | 2025 | Clear+Brilliant |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Mousse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.